MD3559009T2 - Compoziții și metode de inhibare a activității arginazei - Google Patents

Compoziții și metode de inhibare a activității arginazei Download PDF

Info

Publication number: MD3559009T2
Authority: MD; Moldova
Prior art keywords: compound; cancer; formula; compounds; use according
Prior art date: 2016-12-22

Application number

MDE20191232T

Other languages

English (en)

Romanian (ro)

Inventor

Eric B Sjogren

Jim Li

Lijing Chen

Roland J Billedeau

Timothy F Stanton

Zandt Michael Van

Darren Whitehouse

Gunnar E Jagdmann Jr

Lene Raunkj?r PETERSEN

Francesco Parlati

Matthew I Gross

Original Assignee

Calithera Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-22

Filing date

2017-12-22

Publication date

2021-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3559009(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-22 Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc

2021-07-31 Publication of MD3559009T2 publication Critical patent/MD3559009T2/ro

Links

238000000034 method Methods 0.000 title claims abstract description 88
102000004452 Arginase Human genes 0.000 title abstract description 24
108700024123 Arginases Proteins 0.000 title abstract description 24
230000002401 inhibitory effect Effects 0.000 title abstract description 7
239000000203 mixture Substances 0.000 title description 114
230000000694 effects Effects 0.000 title description 13
150000001875 compounds Chemical class 0.000 claims abstract description 427
206010028980 Neoplasm Diseases 0.000 claims abstract description 82
201000011510 cancer Diseases 0.000 claims abstract description 49
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
150000003839 salts Chemical class 0.000 claims description 93
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 78
-1 campotecin Chemical compound 0.000 claims description 56
229960004679 doxorubicin Drugs 0.000 claims description 39
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 38
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 38
229960004316 cisplatin Drugs 0.000 claims description 38
229960004397 cyclophosphamide Drugs 0.000 claims description 38
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 30
229960005420 etoposide Drugs 0.000 claims description 30
238000011282 treatment Methods 0.000 claims description 25
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 24
229940127089 cytotoxic agent Drugs 0.000 claims description 24
229960002949 fluorouracil Drugs 0.000 claims description 24
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 22
239000002246 antineoplastic agent Substances 0.000 claims description 22
229960000485 methotrexate Drugs 0.000 claims description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 15
229960000624 procarbazine Drugs 0.000 claims description 15
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
108010006654 Bleomycin Proteins 0.000 claims description 14
229960001561 bleomycin Drugs 0.000 claims description 14
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 14
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 13
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 13
235000008191 folinic acid Nutrition 0.000 claims description 13
239000011672 folinic acid Substances 0.000 claims description 13
229960001691 leucovorin Drugs 0.000 claims description 13
YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims description 12
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 12
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 12
229960000684 cytarabine Drugs 0.000 claims description 12
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 12
229960000975 daunorubicin Drugs 0.000 claims description 12
239000003937 drug carrier Substances 0.000 claims description 12
229950006370 epacadostat Drugs 0.000 claims description 12
229960002621 pembrolizumab Drugs 0.000 claims description 12
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 11
229930012538 Paclitaxel Natural products 0.000 claims description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 11
229960001156 mitoxantrone Drugs 0.000 claims description 11
229960001592 paclitaxel Drugs 0.000 claims description 11
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 11
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 10
229960001101 ifosfamide Drugs 0.000 claims description 10
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
229960004857 mitomycin Drugs 0.000 claims description 10
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 9
229930192392 Mitomycin Natural products 0.000 claims description 9
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 8
229960004562 carboplatin Drugs 0.000 claims description 8
229960005386 ipilimumab Drugs 0.000 claims description 8
229960003301 nivolumab Drugs 0.000 claims description 8
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
229960003901 dacarbazine Drugs 0.000 claims description 7
206010017758 gastric cancer Diseases 0.000 claims description 7
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 7
229960004961 mechlorethamine Drugs 0.000 claims description 7
201000001441 melanoma Diseases 0.000 claims description 7
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 7
229950010773 pidilizumab Drugs 0.000 claims description 7
201000011549 stomach cancer Diseases 0.000 claims description 7
206010006187 Breast cancer Diseases 0.000 claims description 6
208000026310 Breast neoplasm Diseases 0.000 claims description 6
206010009944 Colon cancer Diseases 0.000 claims description 6
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 6
208000034578 Multiple myelomas Diseases 0.000 claims description 6
206010033128 Ovarian cancer Diseases 0.000 claims description 6
206010060862 Prostate cancer Diseases 0.000 claims description 6
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
229960002247 lomustine Drugs 0.000 claims description 6
201000005202 lung cancer Diseases 0.000 claims description 6
208000020816 lung neoplasm Diseases 0.000 claims description 6
ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 5
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
206010038389 Renal cancer Diseases 0.000 claims description 5
201000010536 head and neck cancer Diseases 0.000 claims description 5
208000014829 head and neck neoplasm Diseases 0.000 claims description 5
229950009034 indoximod Drugs 0.000 claims description 5
201000010982 kidney cancer Diseases 0.000 claims description 5
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 5
229960001924 melphalan Drugs 0.000 claims description 5
229960001428 mercaptopurine Drugs 0.000 claims description 5
229960003347 obinutuzumab Drugs 0.000 claims description 5
229960004641 rituximab Drugs 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
102000015790 Asparaginase Human genes 0.000 claims description 4
108010024976 Asparaginase Proteins 0.000 claims description 4
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 4
206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
229950005186 abagovomab Drugs 0.000 claims description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
229950009084 adecatumumab Drugs 0.000 claims description 4
229950006061 anatumomab mafenatox Drugs 0.000 claims description 4
229950003145 apolizumab Drugs 0.000 claims description 4
229960003272 asparaginase Drugs 0.000 claims description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 4
229960003008 blinatumomab Drugs 0.000 claims description 4
229960005243 carmustine Drugs 0.000 claims description 4
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
229960004630 chlorambucil Drugs 0.000 claims description 4
238000011260 co-administration Methods 0.000 claims description 4
229960001904 epirubicin Drugs 0.000 claims description 4
229950009760 epratuzumab Drugs 0.000 claims description 4
201000004101 esophageal cancer Diseases 0.000 claims description 4
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 4
229960002074 flutamide Drugs 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
229960004635 mesna Drugs 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
229950000106 samalizumab Drugs 0.000 claims description 4
229950007217 tremelimumab Drugs 0.000 claims description 4
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
206010004593 Bile duct cancer Diseases 0.000 claims description 3
206010005003 Bladder cancer Diseases 0.000 claims description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
206010014733 Endometrial cancer Diseases 0.000 claims description 3
206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
108010029961 Filgrastim Proteins 0.000 claims description 3
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
108010069236 Goserelin Proteins 0.000 claims description 3
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 3
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
108010000817 Leuprolide Proteins 0.000 claims description 3
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
229960003852 atezolizumab Drugs 0.000 claims description 3
229960000419 catumaxomab Drugs 0.000 claims description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
229960003957 dexamethasone Drugs 0.000 claims description 3
229950009791 durvalumab Drugs 0.000 claims description 3
229960001842 estramustine Drugs 0.000 claims description 3
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 3
229960004177 filgrastim Drugs 0.000 claims description 3
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
229960005277 gemcitabine Drugs 0.000 claims description 3
229960002913 goserelin Drugs 0.000 claims description 3
229960000908 idarubicin Drugs 0.000 claims description 3
229950007752 isatuximab Drugs 0.000 claims description 3
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
229960004338 leuprorelin Drugs 0.000 claims description 3
229950009090 ocaratuzumab Drugs 0.000 claims description 3
201000005112 urinary bladder cancer Diseases 0.000 claims description 3
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
108010037003 Buserelin Proteins 0.000 claims description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 2
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 2
108010092160 Dactinomycin Proteins 0.000 claims description 2
ZINBFGBAIFRYSH-UHFFFAOYSA-N Demethoxyviridin Natural products CC12C(O)C(O)C(=O)c3coc(C(=O)c4c5CCC(=O)c5ccc14)c23 ZINBFGBAIFRYSH-UHFFFAOYSA-N 0.000 claims description 2
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 2
229940124640 MK-2206 Drugs 0.000 claims description 2
ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 claims description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 2
108010016076 Octreotide Proteins 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
229960000548 alemtuzumab Drugs 0.000 claims description 2
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 2
229960003437 aminoglutethimide Drugs 0.000 claims description 2
229960001220 amsacrine Drugs 0.000 claims description 2
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
229960002932 anastrozole Drugs 0.000 claims description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 2
229960000997 bicalutamide Drugs 0.000 claims description 2
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
229960001467 bortezomib Drugs 0.000 claims description 2
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
229960002719 buserelin Drugs 0.000 claims description 2
229960002092 busulfan Drugs 0.000 claims description 2
229960004117 capecitabine Drugs 0.000 claims description 2
BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
229960002438 carfilzomib Drugs 0.000 claims description 2
108010021331 carfilzomib Proteins 0.000 claims description 2
229960003677 chloroquine Drugs 0.000 claims description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 2
229960002436 cladribine Drugs 0.000 claims description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 2
229960002286 clodronic acid Drugs 0.000 claims description 2
229960002271 cobimetinib Drugs 0.000 claims description 2
RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 2
229960001338 colchicine Drugs 0.000 claims description 2
238000000315 cryotherapy Methods 0.000 claims description 2
229960003843 cyproterone Drugs 0.000 claims description 2
DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims description 2
229960000640 dactinomycin Drugs 0.000 claims description 2
SWJBYJJNDIXFSA-KUHUBIRLSA-N demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 claims description 2
229940120124 dichloroacetate Drugs 0.000 claims description 2
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 2
NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims description 2
229960003839 dienestrol Drugs 0.000 claims description 2
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 2
229960000452 diethylstilbestrol Drugs 0.000 claims description 2
229960003668 docetaxel Drugs 0.000 claims description 2
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
229960001433 erlotinib Drugs 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229930182833 estradiol Natural products 0.000 claims description 2
229960005167 everolimus Drugs 0.000 claims description 2
229960000255 exemestane Drugs 0.000 claims description 2
229960000390 fludarabine Drugs 0.000 claims description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims description 2
229960001751 fluoxymesterone Drugs 0.000 claims description 2
229940045109 genistein Drugs 0.000 claims description 2
235000006539 genistein Nutrition 0.000 claims description 2
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 2
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 2
229960002411 imatinib Drugs 0.000 claims description 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims description 2
229960004768 irinotecan Drugs 0.000 claims description 2
229960004942 lenalidomide Drugs 0.000 claims description 2
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
229960003881 letrozole Drugs 0.000 claims description 2
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
229960001614 levamisole Drugs 0.000 claims description 2
WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims description 2
229960003538 lonidamine Drugs 0.000 claims description 2
229960004616 medroxyprogesterone Drugs 0.000 claims description 2
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
229960003105 metformin Drugs 0.000 claims description 2
PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 2
229960003775 miltefosine Drugs 0.000 claims description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
229960000350 mitotane Drugs 0.000 claims description 2
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 2
229960002653 nilutamide Drugs 0.000 claims description 2
229950006344 nocodazole Drugs 0.000 claims description 2
229960002700 octreotide Drugs 0.000 claims description 2
229960002450 ofatumumab Drugs 0.000 claims description 2
229960000572 olaparib Drugs 0.000 claims description 2
FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
229960001756 oxaliplatin Drugs 0.000 claims description 2
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 2
229940046231 pamidronate Drugs 0.000 claims description 2
CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
229960000639 pazopanib Drugs 0.000 claims description 2
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
229960002340 pentostatin Drugs 0.000 claims description 2
229960003171 plicamycin Drugs 0.000 claims description 2
229960000688 pomalidomide Drugs 0.000 claims description 2
UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
238000001959 radiotherapy Methods 0.000 claims description 2
229960004432 raltitrexed Drugs 0.000 claims description 2
HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
229950004707 rucaparib Drugs 0.000 claims description 2
CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 2
229950010746 selumetinib Drugs 0.000 claims description 2
201000000849 skin cancer Diseases 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
238000002604 ultrasonography Methods 0.000 claims description 2
208000026900 bile duct neoplasm Diseases 0.000 claims 2
208000006990 cholangiocarcinoma Diseases 0.000 claims 2
229950004101 inotuzumab ozogamicin Drugs 0.000 claims 2
JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims 1
206010027406 Mesothelioma Diseases 0.000 claims 1
229950002916 avelumab Drugs 0.000 claims 1
210000003445 biliary tract Anatomy 0.000 claims 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
239000003112 inhibitor Substances 0.000 abstract description 159
102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 142
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 77
125000000217 alkyl group Chemical group 0.000 description 70
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 54
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
125000003118 aryl group Chemical group 0.000 description 46
239000000243 solution Substances 0.000 description 44
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
239000003814 drug Substances 0.000 description 37
125000004429 atom Chemical group 0.000 description 36
229960004528 vincristine Drugs 0.000 description 31
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 31
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 30
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
125000004122 cyclic group Chemical group 0.000 description 29
125000000753 cycloalkyl group Chemical group 0.000 description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 28
229960004618 prednisone Drugs 0.000 description 28
125000001072 heteroaryl group Chemical group 0.000 description 27
229940125773 compound 10 Drugs 0.000 description 26
235000019441 ethanol Nutrition 0.000 description 26
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 26
229940079593 drug Drugs 0.000 description 25
APJSHECCIRQQDV-ZRDIBKRKSA-N (e)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid Chemical compound CCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(\C=C\C(O)=O)=CC=C1O APJSHECCIRQQDV-ZRDIBKRKSA-N 0.000 description 24
150000002148 esters Chemical class 0.000 description 24
125000000592 heterocycloalkyl group Chemical group 0.000 description 23
125000001424 substituent group Chemical group 0.000 description 23
229910052739 hydrogen Inorganic materials 0.000 description 22
229940080328 Arginase inhibitor Drugs 0.000 description 21
125000001183 hydrocarbyl group Chemical group 0.000 description 21
239000000543 intermediate Substances 0.000 description 21
230000001225 therapeutic effect Effects 0.000 description 21
210000004027 cell Anatomy 0.000 description 20
201000010099 disease Diseases 0.000 description 20
239000000843 powder Substances 0.000 description 20
229920006395 saturated elastomer Polymers 0.000 description 20
235000019439 ethyl acetate Nutrition 0.000 description 19
239000001257 hydrogen Substances 0.000 description 19
239000007787 solid Substances 0.000 description 19
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 18
239000003795 chemical substances by application Substances 0.000 description 18
229960003048 vinblastine Drugs 0.000 description 18
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 18
241000699670 Mus sp. Species 0.000 description 17
125000000304 alkynyl group Chemical group 0.000 description 17
125000000623 heterocyclic group Chemical group 0.000 description 17
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
239000000725 suspension Substances 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
238000009472 formulation Methods 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
125000003342 alkenyl group Chemical group 0.000 description 14
125000003545 alkoxy group Chemical group 0.000 description 14
125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 14
238000005160 1H NMR spectroscopy Methods 0.000 description 13
125000004432 carbon atom Chemical group C* 0.000 description 13
238000002648 combination therapy Methods 0.000 description 13
238000004821 distillation Methods 0.000 description 13
125000005842 heteroatom Chemical group 0.000 description 13
125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
239000000463 material Substances 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
238000010521 absorption reaction Methods 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
229940124597 therapeutic agent Drugs 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
239000004480 active ingredient Substances 0.000 description 11
239000000546 pharmaceutical excipient Substances 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
239000004475 Arginine Substances 0.000 description 10
KCLVFKHTAIRPCT-GOGYHYQUSA-N C(C1=CC=CC=C1)OC(=O)[C@@]1(CN(C[C@@H]1CCCB1OC(C(O1)(C)C)(C)C)C([C@H](C)NC(=O)OC(C)(C)C)=O)N=[N+]=[N-] Chemical compound C(C1=CC=CC=C1)OC(=O)[C@@]1(CN(C[C@@H]1CCCB1OC(C(O1)(C)C)(C)C)C([C@H](C)NC(=O)OC(C)(C)C)=O)N=[N+]=[N-] KCLVFKHTAIRPCT-GOGYHYQUSA-N 0.000 description 10
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
125000002252 acyl group Chemical group 0.000 description 10
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
235000009697 arginine Nutrition 0.000 description 10
125000003710 aryl alkyl group Chemical group 0.000 description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
125000004475 heteroaralkyl group Chemical group 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
239000002775 capsule Substances 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 9
229940002612 prodrug Drugs 0.000 description 9
239000000651 prodrug Substances 0.000 description 9
238000001228 spectrum Methods 0.000 description 9
102000019034 Chemokines Human genes 0.000 description 8
108010012236 Chemokines Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000013078 crystal Substances 0.000 description 8
239000012065 filter cake Substances 0.000 description 8
230000001976 improved effect Effects 0.000 description 8
229910052760 oxygen Inorganic materials 0.000 description 8
239000000523 sample Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
229940045513 CTLA4 antagonist Drugs 0.000 description 7
241000725303 Human immunodeficiency virus Species 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
125000003275 alpha amino acid group Chemical group 0.000 description 7
125000002619 bicyclic group Chemical group 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 7
125000001188 haloalkyl group Chemical group 0.000 description 7
125000001475 halogen functional group Chemical group 0.000 description 7
208000026278 immune system disease Diseases 0.000 description 7
239000007788 liquid Substances 0.000 description 7
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
230000000770 proinflammatory effect Effects 0.000 description 7
239000007921 spray Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000003826 tablet Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
229930006000 Sucrose Natural products 0.000 description 6
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
125000003368 amide group Chemical group 0.000 description 6
150000001408 amides Chemical class 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
239000003963 antioxidant agent Substances 0.000 description 6
235000006708 antioxidants Nutrition 0.000 description 6
239000012298 atmosphere Substances 0.000 description 6
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
238000002619 cancer immunotherapy Methods 0.000 description 6
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
125000004431 deuterium atom Chemical group 0.000 description 6
239000012458 free base Substances 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000007937 lozenge Substances 0.000 description 6
150000002894 organic compounds Chemical class 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000003860 storage Methods 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
239000005720 sucrose Substances 0.000 description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
QYFQYTGNLABMFK-UWJYYQICSA-N CC1(C)OB(CCC[C@H]2CNC[C@@]2(N=[N+]=[N-])C(=O)OCC2=CC=CC=C2)OC1(C)C Chemical compound CC1(C)OB(CCC[C@H]2CNC[C@@]2(N=[N+]=[N-])C(=O)OCC2=CC=CC=C2)OC1(C)C QYFQYTGNLABMFK-UWJYYQICSA-N 0.000 description 5
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
102100026236 Interleukin-8 Human genes 0.000 description 5
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
208000037581 Persistent Infection Diseases 0.000 description 5
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000004913 activation Effects 0.000 description 5
125000004423 acyloxy group Chemical group 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
238000013459 approach Methods 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
239000002585 base Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000006071 cream Substances 0.000 description 5
125000000392 cycloalkenyl group Chemical group 0.000 description 5
238000001035 drying Methods 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
239000008187 granular material Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
238000002513 implantation Methods 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
239000006072 paste Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
238000001179 sorption measurement Methods 0.000 description 5
239000007858 starting material Substances 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000002411 thermogravimetry Methods 0.000 description 5
QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
238000004607 11B NMR spectroscopy Methods 0.000 description 4
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 4
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
208000021309 Germ cell tumor Diseases 0.000 description 4
108090001007 Interleukin-8 Proteins 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241001529936 Murinae Species 0.000 description 4
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
229960003767 alanine Drugs 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000000538 analytical sample Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
229940126086 compound 21 Drugs 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
229910052805 deuterium Inorganic materials 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
239000006260 foam Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
229940045207 immuno-oncology agent Drugs 0.000 description 4
239000002584 immunological anticancer agent Substances 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
229940096397 interleukin-8 Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000002502 liposome Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000010992 reflux Methods 0.000 description 4
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000008107 starch Substances 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000000829 suppository Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000010189 synthetic method Methods 0.000 description 4
239000000454 talc Substances 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 4
229960003087 tioguanine Drugs 0.000 description 4
239000001993 wax Substances 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
239000004912 1,5-cyclooctadiene Substances 0.000 description 3
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
241000416162 Astragalus gummifer Species 0.000 description 3
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
102000008096 B7-H1 Antigen Human genes 0.000 description 3
108010074708 B7-H1 Antigen Proteins 0.000 description 3
102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
108010021064 CTLA-4 Antigen Proteins 0.000 description 3
102000008203 CTLA-4 Antigen Human genes 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
235000010643 Leucaena leucocephala Nutrition 0.000 description 3
240000007472 Leucaena leucocephala Species 0.000 description 3
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
102100036154 Platelet basic protein Human genes 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 3
208000006265 Renal cell carcinoma Diseases 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
108091008874 T cell receptors Proteins 0.000 description 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
229920001615 Tragacanth Polymers 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
208000007502 anemia Diseases 0.000 description 3
MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
125000005620 boronic acid group Chemical group 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
125000002837 carbocyclic group Chemical group 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
229940125846 compound 25 Drugs 0.000 description 3
108010035886 connective tissue-activating peptide Proteins 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000003480 eluent Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
210000003128 head Anatomy 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000007943 implant Substances 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 3
108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
238000000465 moulding Methods 0.000 description 3
201000005962 mycosis fungoides Diseases 0.000 description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
125000006413 ring segment Chemical group 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000012453 solvate Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
229960001603 tamoxifen Drugs 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
235000010487 tragacanth Nutrition 0.000 description 3
239000000196 tragacanth Substances 0.000 description 3
229940116362 tragacanth Drugs 0.000 description 3
230000009466 transformation Effects 0.000 description 3
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
OFIYNISEFIEQBC-JTQLQIEISA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@@H](C)C(=O)ON1C(CCC1=O)=O)C(=O)OCC1=CC=CC=C1 OFIYNISEFIEQBC-JTQLQIEISA-N 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
ZAZPDOYUCVFPOI-UHFFFAOYSA-N 2-methylpropylboronic acid Chemical compound CC(C)CB(O)O ZAZPDOYUCVFPOI-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
101710129000 Arginase-1 Proteins 0.000 description 2
102100021723 Arginase-1 Human genes 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
108010040471 CC Chemokines Proteins 0.000 description 2
102000001902 CC Chemokines Human genes 0.000 description 2
108050006947 CXC Chemokine Proteins 0.000 description 2
102000019388 CXC chemokine Human genes 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
102100023688 Eotaxin Human genes 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
102000009127 Glutaminase Human genes 0.000 description 2
108010073324 Glutaminase Proteins 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000021519 Hodgkin lymphoma Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 2
101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 2
HQMLIDZJXVVKCW-REOHCLBHSA-N L-alaninamide Chemical compound C[C@H](N)C(N)=O HQMLIDZJXVVKCW-REOHCLBHSA-N 0.000 description 2
235000014852 L-arginine Nutrition 0.000 description 2
229930064664 L-arginine Natural products 0.000 description 2
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000003445 Mouth Neoplasms Diseases 0.000 description 2
101150097381 Mtor gene Proteins 0.000 description 2
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
KHYUVMDGLZAKKR-MJVIPROJSA-N N[C@]12[C@H](CN(C1)C([C@H](C)N)=O)CCCB(OC2=O)OC(C)C Chemical compound N[C@]12[C@H](CN(C1)C([C@H](C)N)=O)CCCB(OC2=O)OC(C)C KHYUVMDGLZAKKR-MJVIPROJSA-N 0.000 description 2
OAPYQDPDOYVVIE-MJVIPROJSA-N N[C@]12[C@H](CN(C1)C([C@H](C)N)=O)CCCB(OC2=O)OCCC Chemical compound N[C@]12[C@H](CN(C1)C([C@H](C)N)=O)CCCB(OC2=O)OCCC OAPYQDPDOYVVIE-MJVIPROJSA-N 0.000 description 2
206010028729 Nasal cavity cancer Diseases 0.000 description 2
206010028767 Nasal sinus cancer Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 2
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000007641 Pinealoma Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102100030304 Platelet factor 4 Human genes 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
101000655609 Streptomyces azureus Thiostrepton Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000004183 alkoxy alkyl group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
229960000473 altretamine Drugs 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
239000002269 analeptic agent Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
208000002399 aphthous stomatitis Diseases 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940126208 compound 22 Drugs 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000013256 coordination polymer Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
238000003795 desorption Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
208000014616 embryonal neoplasm Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
201000002491 encephalomyelitis Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000004907 flux Effects 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
102000053089 human ARG1 Human genes 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
108010087599 lactate dehydrogenase 1 Proteins 0.000 description 2
108010088076 lactate dehydrogenase 2 Proteins 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
201000005296 lung carcinoma Diseases 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000002895 organic esters Chemical class 0.000 description 2
201000007052 paranasal sinus cancer Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
230000037361 pathway Effects 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
208000010626 plasma cell neoplasm Diseases 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
125000003367 polycyclic group Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000003380 propellant Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
208000012201 sexual and gender identity disease Diseases 0.000 description 2
208000015891 sexual disease Diseases 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
150000007970 thio esters Chemical class 0.000 description 2
208000008732 thymoma Diseases 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 1
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical compound OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 description 1
OOHQXLBZBXABCV-QMMMGPOBSA-N (2s)-3-phenyl-2-(trifluoromethylamino)propanoic acid Chemical compound FC(F)(F)N[C@H](C(=O)O)CC1=CC=CC=C1 OOHQXLBZBXABCV-QMMMGPOBSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 1
DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
GFWBKUDRXMQSFD-FJXQXJEOSA-M 3-aminopropanoyl-[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]azanide;zinc Chemical compound [Zn].NCCC(=O)[N-][C@H](C(O)=O)CC1=CN=CN1 GFWBKUDRXMQSFD-FJXQXJEOSA-M 0.000 description 1
LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
QSVDFJNXDKTKTJ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indene Chemical compound C1CCCC2=C1CC=C2 QSVDFJNXDKTKTJ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
208000000230 African Trypanosomiasis Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010001935 American trypanosomiasis Diseases 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
102100030356 Arginase-2, mitochondrial Human genes 0.000 description 1
101710186578 Arginase-2, mitochondrial Proteins 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
108050005711 C Chemokine Proteins 0.000 description 1
102000017483 C chemokine Human genes 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
125000000172 C5-C10 aryl group Chemical group 0.000 description 1
125000000041 C6-C10 aryl group Chemical group 0.000 description 1
KEJVDWDXICTOEH-YEWWUXTCSA-N C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@](C1)(N=[N+]=[N-])C(=O)OCC1=CC=CC=C1 Chemical compound C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@](C1)(N=[N+]=[N-])C(=O)OCC1=CC=CC=C1 KEJVDWDXICTOEH-YEWWUXTCSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007275 Carcinoid tumour Diseases 0.000 description 1
206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
208000024699 Chagas disease Diseases 0.000 description 1
229940123150 Chelating agent Drugs 0.000 description 1
102000001326 Chemokine CCL4 Human genes 0.000 description 1
108010055165 Chemokine CCL4 Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
102000016680 Dioxygenases Human genes 0.000 description 1
108010028143 Dioxygenases Proteins 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101710139422 Eotaxin Proteins 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108010039731 Fatty Acid Synthases Proteins 0.000 description 1
102000015303 Fatty Acid Synthases Human genes 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
102000042092 Glucose transporter family Human genes 0.000 description 1
108091052347 Glucose transporter family Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000037982 Immune checkpoint proteins Human genes 0.000 description 1
108091008036 Immune checkpoint proteins Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
206010061252 Intraocular melanoma Diseases 0.000 description 1
208000009164 Islet Cell Adenoma Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
206010062038 Lip neoplasm Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000004059 Male Breast Neoplasms Diseases 0.000 description 1
206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
206010028470 Mycoplasma infections Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
AGIHMFPQGZFXJO-FNZWTVRRSA-N N(=[N+]=[N-])[C@]1(CN(C[C@@H]1CCCB1OC(C(O1)(C)C)(C)C)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 Chemical compound N(=[N+]=[N-])[C@]1(CN(C[C@@H]1CCCB1OC(C(O1)(C)C)(C)C)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 AGIHMFPQGZFXJO-FNZWTVRRSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
WBHIBDWMTDFTBQ-KWBADKCTSA-N N[C@@H](C)C(=O)N1C[C@H]2[C@@](C1)(C(OB(CCC2)OCC)=O)N Chemical compound N[C@@H](C)C(=O)N1C[C@H]2[C@@](C1)(C(OB(CCC2)OCC)=O)N WBHIBDWMTDFTBQ-KWBADKCTSA-N 0.000 description 1
DVIOREIQMHDIJD-KWBADKCTSA-N N[C@]12[C@H](CN(C1)C([C@H](CO)N)=O)CCCB(OC2=O)OCC Chemical compound N[C@]12[C@H](CN(C1)C([C@H](CO)N)=O)CCCB(OC2=O)OCC DVIOREIQMHDIJD-KWBADKCTSA-N 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
229910004727 OSO3H Inorganic materials 0.000 description 1
YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
206010031096 Oropharyngeal cancer Diseases 0.000 description 1
206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061332 Paraganglion neoplasm Diseases 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000004362 Penile Induration Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
208000020758 Peyronie disease Diseases 0.000 description 1
208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
206010034811 Pharyngeal cancer Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
206010050487 Pinealoblastoma Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000720974 Protium Species 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
102000011990 Sirtuin Human genes 0.000 description 1
108050002485 Sirtuin Proteins 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
206010072148 Stiff-Person syndrome Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
206010043515 Throat cancer Diseases 0.000 description 1
201000009365 Thymic carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
208000003441 Transfusion reaction Diseases 0.000 description 1
206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046392 Ureteric cancer Diseases 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 1
238000002679 ablation Methods 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960002736 afatinib dimaleate Drugs 0.000 description 1
USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
229960003005 axitinib Drugs 0.000 description 1
RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
FUKOGSUFTZDYOI-BMANNDLBSA-O beacopp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
DCRRIOWFXXDTHV-UHFFFAOYSA-N bicyclo[4.2.0]oct-3-ene Chemical compound C1C=CCC2CCC21 DCRRIOWFXXDTHV-UHFFFAOYSA-N 0.000 description 1
RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 1
201000009036 biliary tract cancer Diseases 0.000 description 1
208000020790 biliary tract neoplasm Diseases 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
IUEWAGVJRJORLA-HZPDHXFCSA-N bmn-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000001273 butane Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
229960001292 cabozantinib Drugs 0.000 description 1
ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
229940095643 calcium hydroxide Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
125000004452 carbocyclyl group Chemical group 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004640 cellular pathway Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
229960001602 ceritinib Drugs 0.000 description 1
WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
208000011654 childhood malignant neoplasm Diseases 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
JCYRRZITSZDHKN-WODMUGMNSA-N chlvpp protocol Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1.OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JCYRRZITSZDHKN-WODMUGMNSA-N 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000004927 clay Substances 0.000 description 1
206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000007819 coupling partner Substances 0.000 description 1
KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
229960005061 crizotinib Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
239000012045 crude solution Substances 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
150000001925 cycloalkenes Chemical group 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
229950006418 dactolisib Drugs 0.000 description 1
JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
238000013480 data collection Methods 0.000 description 1
229960002887 deanol Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
125000005131 dialkylammonium group Chemical group 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
229960003649 eribulin Drugs 0.000 description 1
UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
208000032099 esthesioneuroblastoma Diseases 0.000 description 1
UMYZHWLYICNGRQ-UHFFFAOYSA-N ethanol;heptane Chemical compound CCO.CCCCCCC UMYZHWLYICNGRQ-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
229960002011 fludrocortisone Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
201000010235 heart cancer Diseases 0.000 description 1
208000024348 heart neoplasm Diseases 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
201000001505 hemoglobinuria Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
208000009601 hereditary spherocytosis Diseases 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
201000008298 histiocytosis Diseases 0.000 description 1
208000029080 human African trypanosomiasis Diseases 0.000 description 1
239000003906 humectant Substances 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
238000006197 hydroboration reaction Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
201000006866 hypopharynx cancer Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
229960002014 ixabepilone Drugs 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
239000010410 layer Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000000088 lip Anatomy 0.000 description 1
201000006721 lip cancer Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
208000030173 low grade glioma Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000003175 male breast cancer Diseases 0.000 description 1
208000010907 male breast carcinoma Diseases 0.000 description 1
208000006178 malignant mesothelioma Diseases 0.000 description 1
208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000008203 medulloepithelioma Diseases 0.000 description 1
229960001786 megestrol Drugs 0.000 description 1
JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
229950004847 navitoclax Drugs 0.000 description 1
JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000008106 ocular cancer Diseases 0.000 description 1
201000002575 ocular melanoma Diseases 0.000 description 1
201000005443 oral cavity cancer Diseases 0.000 description 1
231100000822 oral exposure Toxicity 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
201000006958 oropharynx cancer Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
208000021284 ovarian germ cell tumor Diseases 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
229950007318 ozogamicin Drugs 0.000 description 1
KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
208000029211 papillomatosis Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
208000007312 paraganglioma Diseases 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
229960005079 pemetrexed Drugs 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
239000002304 perfume Substances 0.000 description 1
SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
229950010632 perifosine Drugs 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
201000003113 pineoblastoma Diseases 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940056457 promace Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
ADPQWEGXWVSSKZ-UHFFFAOYSA-N pyrrolidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)C1 ADPQWEGXWVSSKZ-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 1
229960002633 ramucirumab Drugs 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229910052702 rhenium Inorganic materials 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
229960003452 romidepsin Drugs 0.000 description 1
OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
108010091666 romidepsin Proteins 0.000 description 1
DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003354 serine derivatives Chemical class 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
201000002612 sleeping sickness Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
229940100996 sodium bisulfate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940001482 sodium sulfite Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
229960003787 sorafenib Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
206010062261 spinal cord neoplasm Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
208000037969 squamous neck cancer Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
125000004426 substituted alkynyl group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
229960001796 sunitinib Drugs 0.000 description 1
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
208000037905 systemic hypertension Diseases 0.000 description 1
229950004550 talazoparib Drugs 0.000 description 1
PRAAPINBUWJLGA-UHFFFAOYSA-N telaglenastat Chemical group FC(F)(F)OC1=CC=CC(CC(=O)NC=2N=NC(CCCCC=3SC(NC(=O)CC=4N=CC=CC=4)=NN=3)=CC=2)=C1 PRAAPINBUWJLGA-UHFFFAOYSA-N 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
FMKOLWIQHDLUPE-UHFFFAOYSA-N tert-butyl 3-oxo-4-prop-2-enylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CC=C)C(=O)C1 FMKOLWIQHDLUPE-UHFFFAOYSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
MCZDHTKJGDCTAE-UHFFFAOYSA-M tetrabutylazanium;acetate Chemical compound CC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC MCZDHTKJGDCTAE-UHFFFAOYSA-M 0.000 description 1
UQCWXKSHRQJGPH-UHFFFAOYSA-M tetrabutylazanium;fluoride;hydrate Chemical compound O.[F-].CCCC[N+](CCCC)(CCCC)CCCC UQCWXKSHRQJGPH-UHFFFAOYSA-M 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
238000001757 thermogravimetry curve Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
229960004066 trametinib Drugs 0.000 description 1
LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
ZHKMVECXITZAPL-SNSGICDFSA-N tsvpp protocol Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ZHKMVECXITZAPL-SNSGICDFSA-N 0.000 description 1
208000009999 tuberous sclerosis Diseases 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000037965 uterine sarcoma Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
229950011257 veliparib Drugs 0.000 description 1
PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
235000016804 zinc Nutrition 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
235000014692 zinc oxide Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Oncology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

MDE20191232T 2016-12-22 2017-12-22 Compoziții și metode de inhibare a activității arginazei MD3559009T2 (ro)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662438092P	2016-12-22	2016-12-22
US201662439614P	2016-12-28	2016-12-28
PCT/US2017/068307 WO2018119440A1 (fr)	2016-12-22	2017-12-22	Compositions et procédés pour inhiber l'activité de l'arginase

Publications (1)

Publication Number	Publication Date
MD3559009T2 true MD3559009T2 (ro)	2021-07-31

Family

ID=60972528

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MDE20191232T MD3559009T2 (ro)	2016-12-22	2017-12-22	Compoziții și metode de inhibare a activității arginazei

Country Status (33)

Country	Link
US (4)	US10287303B2 (fr)
EP (2)	EP3842442B1 (fr)
JP (2)	JP7018949B2 (fr)
KR (1)	KR102579849B1 (fr)
CN (2)	CN110382508B (fr)
AU (2)	AU2017382405B2 (fr)
BR (1)	BR112019012589B1 (fr)
CA (1)	CA3046987A1 (fr)
CL (1)	CL2019001711A1 (fr)
CO (1)	CO2019007839A2 (fr)
CR (1)	CR20190339A (fr)
CY (1)	CY1124483T1 (fr)
DK (2)	DK3842442T3 (fr)
EC (1)	ECSP19045511A (fr)
ES (2)	ES2881395T3 (fr)
HR (1)	HRP20210848T1 (fr)
HU (1)	HUE054272T2 (fr)
IL (2)	IL292677A (fr)
LT (1)	LT3559009T (fr)
MD (1)	MD3559009T2 (fr)
MX (2)	MX378460B (fr)
MY (1)	MY197478A (fr)
NZ (1)	NZ754364A (fr)
PE (1)	PE20191541A1 (fr)
PH (1)	PH12019501396A1 (fr)
PL (1)	PL3559009T3 (fr)
PT (1)	PT3559009T (fr)
RS (1)	RS61996B1 (fr)
SG (2)	SG10201911243WA (fr)
SI (1)	SI3559009T1 (fr)
SM (1)	SMT202100573T1 (fr)
TW (1)	TWI818902B (fr)
WO (1)	WO2018119440A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2632927T3 (en)	2010-10-26	2016-04-11	Mars Inc	Boronates AS ARGINSASEINHIBITORER
TW201718581A (zh)	2015-10-19	2017-06-01	英塞特公司	作為免疫調節劑之雜環化合物
WO2017087777A1 (fr)	2015-11-19	2017-05-26	Incyte Corporation	Composés hétérocycliques utilisés comme immunomodulateurs
US20170174679A1 (en)	2015-12-22	2017-06-22	Incyte Corporation	Heterocyclic compounds as immunomodulators
EP3452476B1 (fr)	2016-05-06	2021-12-15	Incyte Corporation	Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (fr)	2016-05-26	2017-11-30	Incyte Corporation	Composés hétérocycliques utilisés comme immunomodulateurs
SMT202200392T1 (it)	2016-06-20	2022-11-18	Incyte Corp	Composti eterociclici come immunomodulatori
ES2930092T3 (es)	2016-07-14	2022-12-07	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
WO2018044783A1 (fr)	2016-08-29	2018-03-08	Incyte Corporation	Composés hétérocycliques utilisés comme immunomodulateurs
ES2934230T3 (es)	2016-12-22	2023-02-20	Incyte Corp	Derivados de benzooxazol como inmunomoduladores
AU2017382405B2 (en) *	2016-12-22	2021-12-16	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
CN110267953B (zh) *	2016-12-22	2022-12-20	因赛特公司	四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂
US20180179179A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
EP3558963B1 (fr)	2016-12-22	2022-03-23	Incyte Corporation	Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
EP3558989B1 (fr)	2016-12-22	2021-04-14	Incyte Corporation	Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
CN108322295B (zh)	2017-01-17	2021-12-24	维沃移动通信有限公司	一种边带信息的发送方法、接收方法、发送端和接收端
CN117180290A (zh)	2018-02-17	2023-12-08	阿斯利康(瑞典)有限公司	精氨酸酶抑制剂及其使用方法
PL3774843T3 (pl)	2018-03-29	2022-11-14	Molecure Sa	Dipeptydowe pochodne piperydyny
PL3774791T3 (pl)	2018-03-30	2023-06-05	Incyte Corporation	Związki heterocykliczne jako immunomodulatory
TWI821288B (zh)	2018-05-11	2023-11-11	美商英塞特公司	作為免疫調節劑之雜環化合物
US11952392B2 (en) *	2018-08-22	2024-04-09	Astrazeneca Ab	Arginase inhibitors and methods of use thereof
EP3897622A4 (fr)	2018-12-18	2022-09-28	Merck Sharp & Dohme Corp.	Inhibiteurs d'arginase et procédés d'utilisation
HUE062968T2 (hu) *	2019-02-08	2023-12-28	Astrazeneca Ab	Argináz gátlók és eljárás azok alkalmazására
US11753406B2 (en)	2019-08-09	2023-09-12	Incyte Corporation	Salts of a PD-1/PD-L1 inhibitor
JP7559059B2 (ja)	2019-09-30	2024-10-01	インサイト・コーポレイション	免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
CN110759843A (zh) *	2019-09-30	2020-02-07	东北师范大学	一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) *	2019-11-06	2020-01-31	南京谷睿生物科技有限公司	一种化合物及其制备方法和医药上的应用
CR20220237A (es)	2019-11-11	2022-08-05	Incyte Corp	Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
WO2021257863A1 (fr)	2020-06-19	2021-12-23	Incyte Corporation	Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11691971B2 (en)	2020-06-19	2023-07-04	Incyte Corporation	Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006456A1 (fr)	2020-07-02	2022-01-06	Incyte Corporation	Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
MX2023000056A (es)	2020-07-02	2023-04-12	Incyte Corp	Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
WO2022016195A1 (fr) *	2020-07-17	2022-01-20	Incyte Corporation	Procédés de préparation d'inhibiteurs d'arginase et leurs intermédiaires synthétiques
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
TW202233615A (zh)	2020-11-06	2022-09-01	美商英塞特公司	Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US11866434B2 (en)	2020-11-06	2024-01-09	Incyte Corporation	Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
WO2022099018A1 (fr)	2020-11-06	2022-05-12	Incyte Corporation	Procédé de préparation d'un inhibiteur de pd-1/pd-l1
CN112387262B (zh) *	2020-11-10	2021-12-07	泰州学院	一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
WO2022140231A1 (fr)	2020-12-21	2022-06-30	Incyte Corporation	Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
TW202228720A (zh)	2020-12-22	2022-08-01	波蘭商昂科艾倫迪治療法股份公司	精胺酸酶抑制劑及其使用方法
TW202302589A (zh)	2021-02-25	2023-01-16	美商英塞特公司	作為ｊａｋ２ｖ６１７ｆ抑制劑之螺環內醯胺
EP4460585A2 (fr) *	2022-01-07	2024-11-13	The Trustees of Columbia University in the City of New York	Inhibition de la synthèse et/ou de la signalisation de la kynurénine pour traiter la leucémie et la myélodysplasie
MX2024011378A (es)	2022-03-17	2024-09-23	Incyte Corp	Compuestos de urea triciclica como inhibidores de la variante v617f de la cinasa de janus 2 (jak2).
US20240190876A1 (en)	2022-10-21	2024-06-13	Incyte Corporation	Tricyclic Urea Compounds As JAK2 V617F Inhibitors
TW202440086A (zh)	2023-03-13	2024-10-16	美商英塞特公司	作為激酶抑制劑之雙環脲

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4172896A (en)	1978-06-05	1979-10-30	Dainippon Pharmaceutical Co., Ltd.	Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
GB9217295D0 (en)	1992-08-14	1992-09-30	Wellcome Found	Controlled released tablets
GB9315856D0 (en)	1993-07-30	1993-09-15	Wellcome Found	Stabilized pharmaceutical
US5541231A (en)	1993-07-30	1996-07-30	Glaxo Wellcome Inc.	Stabilized Pharmaceutical
US5358970A (en)	1993-08-12	1994-10-25	Burroughs Wellcome Co.	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6403609B1 (en)	1997-07-29	2002-06-11	Alcon Manufacturing, Ltd.	Ophthalmic compositions containing galactomannan polymers and borate
EP1049660A1 (fr)	1997-10-10	2000-11-08	The Trustees Of The University Of Pennsylvania	Compositions et procedes pour inhiber l'activite de l'arginase
JP2002501892A (ja)	1998-01-29	2002-01-22	セプラコアインコーポレーテッド	光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20040063666A1 (en)	1998-10-09	2004-04-01	David Christianson	Compositions for inhibiting arginase activity
US8889112B2 (en)	1999-09-16	2014-11-18	Ocularis Pharma, Llc	Ophthalmic formulations including selective alpha 1 antagonists
IL152738A0 (en)	2000-05-10	2003-06-24	Mayo Foundation	Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
AU2001275870A1 (en)	2000-07-06	2002-01-21	Fal Diagnostics	Methods and kits for the detection of arginine compounds
CA2431080A1 (fr)	2003-06-02	2004-12-02	Catherine Adele O'brien	Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US8512717B2 (en)	2003-08-07	2013-08-20	Allergan, Inc.	Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en)	2003-09-12	2005-03-17	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (fr)	2005-07-01	2009-11-11	Univ Johns Hopkins	Arginase ii: traitement ciblé du vieillissement cardiaque et de l'insuffisance cardiaque
WO2007095050A2 (fr)	2006-02-09	2007-08-23	Incyte Corporation	N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase
US20080125470A1 (en)	2006-09-19	2008-05-29	Incyte Corporation	N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080119491A1 (en)	2006-09-19	2008-05-22	Incyte Corporation	Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es)	2006-09-19	2008-02-08	Incyte Corp	Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036652A2 (fr)	2006-09-19	2008-03-27	Incyte Corporation	Amidines servant de modulateurs d'indoléamine 2,3-dioxygénase
US20080182882A1 (en)	2006-11-08	2008-07-31	Incyte Corporation	N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2083812B1 (fr)	2006-11-21	2017-04-05	Rijksuniversiteit Groningen	Utilisation d'inhibiteurs de l'arginase dans le traitement de l'asthme et de la rhinite allergique
EP3443958A1 (fr)	2006-11-22	2019-02-20	Incyte Holdings Corporation	Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinase
JP5386353B2 (ja)	2007-07-12	2014-01-15	山洋電気株式会社	二重反転式軸流送風機
KR20100080798A (ko)	2007-10-12	2010-07-12	레솔빅스 파마슈티칼즈, 인코퍼레이티드	안과 질환의 치료를 위한 옥실리핀 화합물
US10047066B2 (en)	2007-11-30	2018-08-14	Newlink Genetics Corporation	IDO inhibitors
WO2011116299A2 (fr)	2010-03-18	2011-09-22	Colorado State University Research Foundation	Agents d'inhibition des cellules myéloïdes suppressives
US8748469B2 (en)	2008-04-24	2014-06-10	Newlink Genetics Corporation	IDO inhibitors
JP2011519868A (ja)	2008-05-05	2011-07-14	シェーリングコーポレイション	癌を処置するための化学療法剤の連続投与
EA022669B1 (ru)	2008-07-08	2016-02-29	Инсайт Холдингс Корпорейшн	1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
HRP20191433T1 (hr)	2009-01-26	2019-11-15	Univ Pennsylvania	Inhibitori arginaze i metode primjene
JP5835814B2 (ja)	2009-12-31	2015-12-24	イノクリンファーマシューティカルズ，インコーポレイテッド	金属酵素阻害化合物
BR112012027034B1 (pt)	2010-04-22	2020-10-13	Mars, Incorporated	compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
PT2563771E (pt)	2010-04-24	2016-03-31	Viamet Pharmaceuticals Inc	Compostos inibidores de metaloenzimas
SG187757A1 (en) *	2010-08-10	2013-03-28	Rempex Pharmaceuticals Inc	Cyclic boronic acid ester derivatives and therapeutic uses thereof
EA201300282A1 (ru)	2010-08-27	2013-08-30	Мерк Патент Гмбх	Производные триазолопиразина
DK2632927T3 (en)	2010-10-26	2016-04-11	Mars Inc	Boronates AS ARGINSASEINHIBITORER
CA2816088A1 (fr)	2010-10-28	2012-05-03	Viamet Pharmaceuticals, Inc.	Composes inhibiteurs de metalloenzymes
KR20180039185A (ko)	2010-11-13	2018-04-17	이노크린 파마슈티컬즈, 인크.	금속효소 억제제 화합물
US8669274B2 (en)	2010-12-13	2014-03-11	Viamet Pharmaceuticals, Inc.	Metalloenzyme inhibitor compounds
RU2019121905A (ru)	2010-12-31	2019-09-03	Астразенека Юкей Лимитед	Ингибиторы аргиназы и способы их применения
NO2694640T3 (fr)	2011-04-15	2018-03-17
KR20180095109A (ko)	2011-06-19	2018-08-24	비아멧 파마슈티컬즈(엔씨), 인코포레이티드	금속효소 억제제 화합물
CN103842355A (zh)	2011-06-19	2014-06-04	威尔金制药有限公司	金属酶抑制剂化合物
EA025266B1 (ru)	2011-06-23	2016-12-30	Ваймет Фармасьютикалс, Инк.	Соединения, ингибирующие металлоферменты
AU2012300275A1 (en)	2011-08-30	2014-03-06	Innocrin Pharmaceuticals, Inc.	Metalloenzyme inhibitor compounds
CA2852685C (fr)	2011-10-19	2019-02-26	Mars, Incorporated	Inhibiteurs d'arginase et leur application therapeutique
EP2768509B1 (fr)	2011-10-20	2017-03-22	Glaxosmithkline LLC	Azahétérocycles bicycliques substitués et analogues comme modulateurs de la sirtuine
LT2788343T (lt)	2011-12-11	2018-06-11	Viamet Pharmaceuticals (NC), Inc.	Metalo fermentus slopinantys junginiai
CN104136427B (zh)	2012-01-20	2017-03-01	威尔金制药有限公司	金属酶抑制剂化合物
EP2807161B1 (fr)	2012-01-28	2017-10-04	Merck Patent GmbH	Dérivés de triazolo[4,5-d]pyrimidine
EP2817306B1 (fr)	2012-02-21	2015-09-16	Merck Patent GmbH	Dérivés cycliques de diaminopyrimidine comme inhibiteurs de la syk
EP2817310B1 (fr)	2012-02-21	2018-03-21	Merck Patent GmbH	2-amino-[1,2,4]triazolo[1,5-a]pyrazines substituées en 8ème position en tant qu'inhibiteurs de la tyrosine kinase syk et en tant qu'inhibiteurs de la sérine kinase gcn2
EP2822948B1 (fr)	2012-03-07	2016-04-06	Merck Patent GmbH	Dérivés de triazolopyrazine
IN2014DN09678A (fr) *	2012-04-18	2015-07-31	Mars Inc
EP2882746B1 (fr)	2012-08-07	2016-12-07	Merck Patent GmbH	Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
US20150246898A1 (en)	2012-09-12	2015-09-03	Dow Agrosciences Llc	Metalloenzyme inhibitor compounds
WO2014071231A1 (fr)	2012-11-02	2014-05-08	Pharmacyclics, Inc.	Thérapie adjuvante par inhibiteur de kinase de la famille tec
WO2014117090A1 (fr)	2013-01-28	2014-07-31	Viamet Pharmaceuticals, Inc.	Composés inhibiteurs de métalloenzyme
CN105026397B (zh)	2013-03-05	2017-06-30	默克专利股份公司	作为抗癌剂的9‑(芳基或杂芳基)‑2‑(吡唑基、吡咯烷基或环戊基)氨基嘌呤衍生物
CN105026398B (zh)	2013-03-05	2018-05-18	默克专利股份公司	用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
EP3366678A1 (fr)	2013-03-14	2018-08-29	Newlink Genetics Corporation	Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
WO2014141110A2 (fr)	2013-03-14	2014-09-18	Curadev Pharma Pvt. Ltd.	Aminonitriles en tant qu'inhibiteurs de la voie de la kynurénine
EA201591610A1 (ru)	2013-03-14	2015-12-30	Курадев Фарма Прайвит Лтд.	Ингибиторы кинуренинового пути
CA2907178A1 (fr)	2013-03-15	2014-09-25	Bristol-Myers Squibb Company	Inhibiteurs de l'ido
KR20150128891A (ko)	2013-03-15	2015-11-18	브리스톨-마이어스 스큅 컴퍼니	인돌아민 2,3-디옥시게나제 (ido)의 억제제
EP2994471B1 (fr)	2013-05-06	2017-05-17	Merck Patent GmbH	Macrocycles utilisés en tant qu'inhibiteurs de kinases
CA2913914C (fr)	2013-05-28	2018-03-20	Viamet Pharmaceuticals, Inc.	Compositions fongicides
US9765018B2 (en)	2013-07-01	2017-09-19	Bristol-Myers Squibb Company	IDO inhibitors
JP6478991B2 (ja)	2013-07-11	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｉｄｏ阻害剤
US10821178B2 (en)	2013-07-29	2020-11-03	Board Of Regents Of The University Of Nebraska	Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells
JP6371851B2 (ja)	2013-08-27	2018-08-08	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｉｄｏ阻害剤
EP3060251A4 (fr)	2013-10-25	2017-12-06	Pharmacyclics LLC	Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie
JP6461953B2 (ja)	2013-11-08	2019-01-30	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	インドールアミン２，３−ジオキシゲナーゼ阻害剤の合成のためのプロセス
US20170037125A1 (en)	2014-02-04	2017-02-09	Incyte Corporation	Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
WO2015160664A1 (fr)	2014-04-15	2015-10-22	Dow Agrosciences Llc	Composés inhibiteurs de métallo-enzymes en tant que fongicides
KR20160144410A (ko)	2014-04-15	2016-12-16	다우 아그로사이언시즈 엘엘씨	살진균제로서의 금속효소 억제제 화합물
RU2016149812A (ru)	2014-06-06	2018-07-17	Флексус Байосайенсиз, Инк.	Иммунорегулирующие средства
TW201619133A (zh)	2014-08-21	2016-06-01	裘拉德製藥私人有限公司	新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
KR20170044144A (ko)	2014-09-05	2017-04-24	메르크 파텐트 게엠베하	암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물
CN105879030A (zh)	2014-09-30	2016-08-24	复旦大学	治疗肿瘤的增效药物复合物及其制备方法
GB201417369D0 (en)	2014-10-01	2014-11-12	Redx Pharma Ltd	Compounds
WO2016057986A1 (fr)	2014-10-10	2016-04-14	The Trustees Of Columbia University In The City Of New York	Constructions d'épitopes en tandem pour la présentation d'épitopes cd4 et cd8, et leurs utilisations
GB201418300D0 (en)	2014-10-15	2014-11-26	Redx Pharma Ltd	Compounds
UY36391A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
WO2016073738A2 (fr)	2014-11-05	2016-05-12	Flexus Biosciences, Inc.	Agents immunorégulateurs
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016130501A1 (fr)	2015-02-09	2016-08-18	Incyte Corporation	Composés aza-hétéroaryle en tant qu'inhibiteurs de pi3k-gamma
KR20170129896A (ko)	2015-03-20	2017-11-27	새미 오유 오피요	악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
US9944647B2 (en)	2015-04-03	2018-04-17	Incyte Corporation	Heterocyclic compounds as LSD1 inhibitors
WO2016161269A1 (fr)	2015-04-03	2016-10-06	Bristol-Myers Squibb Company	Inhibiteurs de l'indoléamine 2,3-dioxygénase pour le traitement du cancer
TW201705955A (zh)	2015-05-14	2017-02-16	輝瑞大藥廠	包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
WO2016196890A1 (fr)	2015-06-04	2016-12-08	Vtv Therapeutics Llc	Inhibiteurs d'hexokinase et leurs procédés d'utilisation
MX385315B (es)	2015-06-23	2025-03-14	Calithera Biosciences Inc	Composiciones y metodos para inhibir actividad de arginasa.
CN108271371B (zh)	2015-10-30	2021-02-09	卡里塞拉生物科学股份公司	用于抑制精氨酸酶活性的组合物和方法
PL417066A1 (pl)	2016-05-04	2017-11-06	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017382405B2 (en)	2016-12-22	2021-12-16	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
CA3062851A1 (fr)	2017-05-12	2018-11-15	Calithera Biosciences, Inc.	Procede de preparation de (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

2017
- 2017-12-22 AU AU2017382405A patent/AU2017382405B2/en not_active Ceased
- 2017-12-22 BR BR112019012589-2A patent/BR112019012589B1/pt not_active IP Right Cessation
- 2017-12-22 SG SG10201911243WA patent/SG10201911243WA/en unknown
- 2017-12-22 SI SI201730835T patent/SI3559009T1/sl unknown
- 2017-12-22 US US15/853,310 patent/US10287303B2/en active Active
- 2017-12-22 KR KR1020197021468A patent/KR102579849B1/ko active Active
- 2017-12-22 EP EP21158664.9A patent/EP3842442B1/fr active Active
- 2017-12-22 HU HUE17829574A patent/HUE054272T2/hu unknown
- 2017-12-22 EP EP17829574.7A patent/EP3559009B1/fr active Active
- 2017-12-22 SG SG10201911240PA patent/SG10201911240PA/en unknown
- 2017-12-22 MD MDE20191232T patent/MD3559009T2/ro unknown
- 2017-12-22 PT PT178295747T patent/PT3559009T/pt unknown
- 2017-12-22 ES ES17829574T patent/ES2881395T3/es active Active
- 2017-12-22 HR HRP20210848TT patent/HRP20210848T1/hr unknown
- 2017-12-22 SM SM20210573T patent/SMT202100573T1/it unknown
- 2017-12-22 IL IL292677A patent/IL292677A/en unknown
- 2017-12-22 LT LTEP17829574.7T patent/LT3559009T/lt unknown
- 2017-12-22 CR CR20190339A patent/CR20190339A/es unknown
- 2017-12-22 DK DK21158664.9T patent/DK3842442T3/da active
- 2017-12-22 PE PE2019001311A patent/PE20191541A1/es unknown
- 2017-12-22 CN CN201780080358.1A patent/CN110382508B/zh active Active
- 2017-12-22 JP JP2019534159A patent/JP7018949B2/ja active Active
- 2017-12-22 WO PCT/US2017/068307 patent/WO2018119440A1/fr not_active Ceased
- 2017-12-22 MX MX2019007471A patent/MX378460B/es unknown
- 2017-12-22 NZ NZ754364A patent/NZ754364A/en not_active IP Right Cessation
- 2017-12-22 CA CA3046987A patent/CA3046987A1/fr active Pending
- 2017-12-22 MY MYPI2019003368A patent/MY197478A/en unknown
- 2017-12-22 CN CN202210836886.8A patent/CN114989205A/zh active Pending
- 2017-12-22 ES ES21158664T patent/ES2970715T3/es active Active
- 2017-12-22 RS RS20210763A patent/RS61996B1/sr unknown
- 2017-12-22 DK DK17829574.7T patent/DK3559009T3/da active
- 2017-12-22 TW TW106145440A patent/TWI818902B/zh active
- 2017-12-22 PL PL17829574T patent/PL3559009T3/pl unknown
2019
- 2019-03-29 US US16/370,857 patent/US10597411B2/en not_active Expired - Fee Related
- 2019-06-18 PH PH12019501396A patent/PH12019501396A1/en unknown
- 2019-06-19 CL CL2019001711A patent/CL2019001711A1/es unknown
- 2019-06-20 MX MX2020013649A patent/MX2020013649A/es unknown
- 2019-06-20 IL IL267532A patent/IL267532B/en unknown
- 2019-06-26 EC ECSENADI201945511A patent/ECSP19045511A/es unknown
- 2019-07-22 CO CONC2019/0007839A patent/CO2019007839A2/es unknown
2020
- 2020-02-14 US US16/792,186 patent/US11021495B2/en active Active
2021
- 2021-01-20 US US17/153,804 patent/US12054501B2/en active Active
- 2021-07-05 CY CY20211100602T patent/CY1124483T1/el unknown
2022
- 2022-02-01 JP JP2022014021A patent/JP2022066199A/ja not_active Abandoned
- 2022-02-17 AU AU2022201072A patent/AU2022201072A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK3842442T3 (da)	2024-02-05
TWI818902B (zh)	2023-10-21
SG10201911243WA (en)	2020-02-27
DK3559009T3 (da)	2021-05-03
CR20190339A (es)	2020-01-10
WO2018119440A1 (fr)	2018-06-28
CA3046987A1 (fr)	2018-06-28
JP2020514271A (ja)	2020-05-21
AU2017382405B2 (en)	2021-12-16
IL267532B (en)	2022-06-01
MY197478A (en)	2023-06-19
CN110382508B (zh)	2022-08-02
MX2020013649A (es)	2021-02-26
US20210261573A1 (en)	2021-08-26
PH12019501396A1 (en)	2019-12-02
SG10201911240PA (en)	2020-02-27
KR102579849B1 (ko)	2023-09-18
US11021495B2 (en)	2021-06-01
TW201828948A (zh)	2018-08-16
ECSP19045511A (es)	2019-10-31
US12054501B2 (en)	2024-08-06
LT3559009T (lt)	2021-06-25
CO2019007839A2 (es)	2019-10-21
PE20191541A1 (es)	2019-10-23
US10597411B2 (en)	2020-03-24
ES2970715T3 (es)	2024-05-30
BR112019012589A2 (pt)	2019-11-19
RS61996B1 (sr)	2021-07-30
KR20190119579A (ko)	2019-10-22
HUE054272T2 (hu)	2021-09-28
EP3842442B1 (fr)	2023-11-01
US20190330244A1 (en)	2019-10-31
SMT202100573T1 (it)	2021-11-12
US10287303B2 (en)	2019-05-14
PT3559009T (pt)	2021-05-04
US20200339607A1 (en)	2020-10-29
MX378460B (es)	2025-03-10
EP3559009B1 (fr)	2021-04-07
JP7018949B2 (ja)	2022-02-14
BR112019012589B1 (pt)	2022-11-29
IL267532A (en)	2019-08-29
HRP20210848T1 (hr)	2021-07-09
CY1124483T1 (el)	2022-07-22
AU2017382405A1 (en)	2019-06-27
US20180222926A1 (en)	2018-08-09
IL292677A (en)	2022-07-01
JP2022066199A (ja)	2022-04-28
EP3842442A1 (fr)	2021-06-30
NZ754364A (en)	2023-04-28
SI3559009T1 (sl)	2021-08-31
PL3559009T3 (pl)	2021-10-25
ES2881395T3 (es)	2021-11-29
AU2022201072A1 (en)	2022-03-10
MX2019007471A (es)	2019-11-05
CN110382508A (zh)	2019-10-25
CN114989205A (zh)	2022-09-02
EP3559009A1 (fr)	2019-10-30
CL2019001711A1 (es)	2020-01-17

Publication	Publication Date	Title
MD3559009T2 (ro)	2021-07-31	Compoziții și metode de inhibare a activității arginazei
AU2020286278B2 (en)	2022-03-17	Compositions and methods for inhibiting arginase activity
HK40056484B (en)	2024-10-25	Compositions and methods for inhibiting arginase activity
HK40056484A (en)	2022-04-01	Compositions and methods for inhibiting arginase activity
HK40011974B (en)	2021-07-23	Compositions and methods for inhibiting arginase activity
HK40011974A (en)	2020-07-17	Compositions and methods for inhibiting arginase activity
EA038517B1 (ru)	2021-09-09	Композиции и способы ингибирования активности аргиназы
HK1252560B (en)	2021-02-11	Compositions and methods for inhibiting arginase activity